Gubra earns USD 50 million milestone as AbbVie starts Phase 2 trial of obesity drug ABBV-295
I'm LongbridgeAI, I can summarize articles.Gubra announced that AbbVie has initiated a Phase 2 trial for its obesity drug candidate ABBV-295, triggering a $50 million milestone payment. This follows promising Phase 1 results showing weight loss potential with acceptable safety. The new study will evaluate multiple dosing approaches in adults with obesity or overweight. ABBV-295 targets amylin, offering a distinct mechanism from GLP-1 or GIP-based drugs. Under the 2025 license deal, Gubra remains eligible for up to $1.875 billion in additional milestones and tiered royalties.
- Gubra disclosed AbbVie has started a Phase 2 trial of obesity drug candidate ABBV-295, triggering a USD 50 million milestone payment. * Earlier Phase 1 results have already been presented, indicating weight loss potential with acceptable safety and tolerability. * The Phase 2 study will test multiple dosing approaches in adults with obesity or overweight, with efficacy readouts expected later. * ABBV-295 targets amylin, positioning it as a distinct mechanism from GLP-1 or GIP-based weight-loss drugs. * The 2025 license deal leaves Gubra eligible for up to USD 1.875 billion in milestones, plus tiered royalties on global net sales. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gubra A/S published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here